Unaudited Financial Results for the quarter ended December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals reported a sharp jump in Q3FY26 revenue to Rs 39.13 crore from Rs 10.58 crore in Q3FY25, a rise of nearly 270% year-on-year. Net profit for the quarter surged to Rs 20.36 crore from Rs 3.16 crore, up about 5.4x. For the nine months ended December 2025, revenue grew to Rs 50.40 crore (from Rs 19.32 crore) and net profit jumped to Rs 23.77 crore (from Rs 4.19 crore). The company also re-appointed Mr Dakshesh Shah as Managing Director for another 5 years and has five subsidiaries (Robotics, Woundcare, Diabetes Tech, Healthtech) currently contributing NIL revenue and NIL profit. The statutory auditor Shah Sanghvi & Associates issued an unqualified review report with no emphasis of matter.
Very strong quarterly performance with revenue and profits multiplying several-fold year-on-year; EBITDA margins also expanded sharply. This is a positive signal for shareholders, though the EPS is lower due to a stock split (face value reduced from Rs 10 to Rs 1) that increased the share count. Investors should note the subsidiaries are not yet contributing to earnings.